This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Ling-Feng Wan, Hong-Bing Zhao, Bo-Yu Xue, Department of Infectious Disease, the Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029, Jiangsu Province, China
Supported by: the Project of the State Administration of Traditional Chinese Medicine, No. JDZX2012060; "Six Big Talent Peak" Project of Jiangsu Province, No. 2013-WSN-044
Correspondence to: Bo-Yu Xue, Professor, Chief Physician, Department of Infectious Disease, the Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, 155 Hanzhong Road, Nanjing 210029, Jiangsu Province, China. 496091201@qq.com
Received: July 9, 2014 Revised: September 11, 2014 Accepted: September 30, 2014 Published online: November 8, 2014
Chronic hepadnavirus infection, alcohol abuse, nonalcoholic fatty liver disease and contact with chemical poisons can lead to chronic liver inflammation. Current studies suggest that chronic inflammation of the liver is an important factor contributing to the occurrence, development and prognosis of liver cancer. Liver cancer is highly malignant and has a poor prognosis and high incidence. For better tumor prevention and treatment, it is important to fully understand the relationship between chronic liver inflammation and liver cancer. In this paper, we review recent progress in understanding the relationship between chronic liver inflammation and liver cancer.
Key Words: Chronic liver disease; Inflammation; Liver cancer
Citation: Wan LF, Zhao HB, Xue BY. Chronic liver inflammation and liver cancer. Shijie Huaren Xiaohua Zazhi 2014; 22(31): 4757-4761
Schütze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, Olsen A, Tjønneland AM, Dahm CC, Overvad K. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study.BMJ. 2011;342:d1584.
[PubMed] [DOI]
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.Hepatology. 2010;51:1820-1832.
[PubMed] [DOI]
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.N Engl J Med. 2003;348:1625-1638.
[PubMed] [DOI]
Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AO, Wong BC, Mizokami M. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.J Hepatol. 2009;50:80-88.
[PubMed] [DOI]
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.Carcinogenesis. 2009;30:1073-1081.
[PubMed] [DOI]
Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells.J Biol Chem. 1999;274:18470-18476.
[PubMed] [DOI]
Takai A, Toyoshima T, Uemura M, Kitawaki Y, Marusawa H, Hiai H, Yamada S, Okazaki IM, Honjo T, Chiba T. A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations.Oncogene. 2009;28:469-478.
[PubMed] [DOI]
Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.Cancer Cell. 2008;14:156-165.
[PubMed] [DOI]
Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways.J Gastroenterol Hepatol. 2007;22 Suppl 1:S108-S111.
[PubMed] [DOI]
Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications.Clin Cancer Res. 2007;13:1362-1366.
[PubMed] [DOI]
Li N, Grivennikov SI, Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment.Cancer Cell. 2011;19:429-431.
[PubMed] [DOI]
Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.Gastroenterology. 2006;130:1117-1128.
[PubMed] [DOI]
Lau CK, Yang ZF, Lam SP, Lam CT, Ngai P, Tam KH, Poon RT, Fan ST. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.Cancer Biol Ther. 2007;6:1900-1907.
[PubMed] [DOI]
Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.Oncogene. 2009;28:961-972.
[PubMed] [DOI]
Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.Cell. 2010;140:197-208.
[PubMed] [DOI]
Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, Huang X, Wang X, Sun B. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.Hepatology. 2013;57:678-688.
[PubMed] [DOI]
Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, Gao Y, Wang X, Sun B. miR-22 promotes HBV-related hepatocellular carcinoma development in males.Clin Cancer Res. 2011;17:5593-5603.
[PubMed] [DOI]
Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.N Engl J Med. 1997;336:1066-1071.
[PubMed] [DOI]
Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.Cancer Cell. 2007;11:119-132.
[PubMed] [DOI]
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer.Nature. 2004;431:461-466.
[PubMed] [DOI]
Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA. A lymphotoxin-driven pathway to hepatocellular carcinoma.Cancer Cell. 2009;16:295-308.
[PubMed] [DOI]
Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.Cell. 2005;121:977-990.
[PubMed] [DOI]